Compare VRTS & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTS | BBNX |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 864.8M | 997.9M |
| IPO Year | 1995 | 2025 |
| Metric | VRTS | BBNX |
|---|---|---|
| Price | $131.81 | $17.62 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $145.50 | $23.80 |
| AVG Volume (30 Days) | 95.5K | ★ 1.4M |
| Earning Date | 10-23-2026 | 10-27-2026 |
| Dividend Yield | ★ 7.45% | N/A |
| EPS Growth | 18.24 | ★ 78.95 |
| EPS | ★ 7.72 | N/A |
| Revenue | N/A | ★ $100,251,000.00 |
| Revenue This Year | N/A | $25.74 |
| Revenue Next Year | N/A | $44.51 |
| P/E Ratio | $17.05 | ★ N/A |
| Revenue Growth | N/A | ★ 53.94 |
| 52 Week Low | $121.61 | $8.80 |
| 52 Week High | $195.00 | $32.71 |
| Indicator | VRTS | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 35.22 | 37.29 |
| Support Level | $124.58 | $15.76 |
| Resistance Level | $149.55 | $18.20 |
| Average True Range (ATR) | 3.79 | 1.08 |
| MACD | 1.17 | -0.46 |
| Stochastic Oscillator | 45.70 | 4.62 |
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.